ZA976331B - New imidazotriazolopyrimidines processes for their preparation and their use as pharmaceutical compositions - Google Patents

New imidazotriazolopyrimidines processes for their preparation and their use as pharmaceutical compositions

Info

Publication number
ZA976331B
ZA976331B ZA976331A ZA976331A ZA976331B ZA 976331 B ZA976331 B ZA 976331B ZA 976331 A ZA976331 A ZA 976331A ZA 976331 A ZA976331 A ZA 976331A ZA 976331 B ZA976331 B ZA 976331B
Authority
ZA
South Africa
Prior art keywords
optionally substituted
alkyl
alkenyl
alkynyl
cycloalkyl
Prior art date
Application number
ZA976331A
Inventor
Ulrike Kuefner-Muehl
Werner Kummer
Gerald Pohl
Wolfram Gaida
Erich Lehr
Joachim Mierau
Thomas Weiser
Original Assignee
Boehringer Ingelheim Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Kg filed Critical Boehringer Ingelheim Kg
Priority claimed from CA002242097A external-priority patent/CA2242097C/en
Publication of ZA976331B publication Critical patent/ZA976331B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

1,2,4-TriazoloÄ1,5-aÜpurin-9-one derivatives of formula (I), and their racemates, enantiomers, diastereomers and/or acid addition salts are new. R1 or R3 and R4 or R5 = H, Z, COOZ, SO2Z, SO2A, COZ, aralkyl, aralkenyl, aralkynyl, A, COOA, SO2A, COA, CONHR or (all optionally substituted) benzyloxycarbonyl, benzylsulphonyl, 4-8C cycloalkenyl, 6-8C cycloalkynyl, benzyl, or benzylcarbonyl; Z = 1-10C alkyl, 3-8C cycloalkyl, 6-10C aryl, heteroaryl (all optionally substituted), 2-10C alkenyl or 2-10C alkynyl; A = optionally substituted 5-7 membered heterocycle (containing one or more of N, S and O as heteroatom(s) and bonded via C); R = H, or phenyl, benzyl or 3-6C cycloalkyl (all optionally substituted), or alkyl, alkenyl or alkynyl (all of up to 10C and optionally substituted by OH, optionally substituted phenyl or optionally substituted amino); R2 = H, OH, NH2, halo, NO2, CF3, COOH, SH, 1-6C alkylthio, SO2Z, benzylsulphonyl, OSO2Z, NHSO2Z, CONHZ, di-(1-10C alkyl or 2-10C alkenyl)-aminocarbonyl, N-(1-10C alkyl)-N-(2-10C alkenyl or alkynyl)-aminocarbonyl, NHCOOZ, OCONHZ, C(=NH)NHZ, OZ, COOZ, OCOZ, SZ, optionally substituted amino, preferably NR8R9, or (all optionally substituted) 1-10C alkyl, 2-10C alkenyl, 2-10C alkynyl, 3-8C cycloalkyl, 5-8C cycloalkanone, 4-8C cycloalkenyl, 6-8C cycloalkynyl, 6-10C aryl, aryl-(1-6C)alkyl, aryl-(2-6C)alkenyl, aryl-(2-6C)alkynyl, cycloalkyl-(1-6C)alkyl, cycloalkyl-(2-6C)alkenyl, cycloalkyl-(2-6C)alkynyl, 5-7 membered heterocycle (containing one or more of O, S and optionally substituted N as heteroatom(s) and linked via C- or N- or via a 1-6C alkyl, 2-6C alkenyl or 2-6C alkynyl bridge), or (all optionally substituted) 1-10C alkyl, 2-10C alkenyl, 2-10C alkynyl, 3-8C cycloalkyl, 5-8C cycloalkanone, 4-8C cycloalkenyl, 6-8C cycloalkynyl, 6-10C aryl, aryl-(1-6C)alkyl, aryl-(2-6C)alkenyl, aryl-(2-6C)alkynyl, cycloalkyl-(1-6C)alkyl, cycloalkyl-(2-6C)alkenyl, cycloalkyl-(2-6C)alkynyl, 5-7 membered heterocycle (containing one or more of O, S and optionally substituted N as heteroatom(s) and linked via C- or N- or via a 1-6C alkyl, 2-6C alkenyl or 2-6C alkynyl bridge), methylenedioxyphenyl, ethylenedioxyphenyl, fluorenyl or optionally substituted group of formula (a)-(e); R6 = as for R2 or CHO; x = 1 or 2; y = 0-2; dotted lines in (a) = optional bonds; Q = H or 1-6C alkyl, but cannot be alkyl if the ring system in (a) contains two double bonds; Y = bond, 1-6C alkylene, 2-6C alkenylene or 2-6C alkynylene; R8, R9 = 1-10C alkyl, 2-10C alkenyl or 2-10C alkynyl (optionally substituted by OH, optionally substituted phenyl, optionally substituted benzyl, optionally substituted amino or 1-6C alkoxy), H, optionally substituted 3-6C cycloalkyl, (CH2)mNHCOOR4; or NR8R9 = saturated or unsaturated 5- or 6- membered ring (optionally containing another O, S or N heteroatom and optionally substituted by 1-4C alkyl, (CH2)nPh, (CH2)nNH2, oxo, ketal (preferably OCH2CH2O), (CH2)nNH-(1-4C alkyl), (CH2)nN(1-8C alkyl)2, (CH2)nNHCOOR10, halo, OR10, CN, NO2, NH2, CH2NR8R9 (sic), OH, COOH, SO3H, COOR10, CONR8R9 (sic) or SO2R10); m = 1-4; n = 2-4; R10 = H, 1-4C alkyl, 2-4C alkenyl, 2-4C alkynyl, or benzyl or phenyl (both optionally substituted by one or more OMe).
ZA976331A 1996-07-20 1997-07-17 New imidazotriazolopyrimidines processes for their preparation and their use as pharmaceutical compositions ZA976331B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19629378A DE19629378A1 (en) 1996-07-20 1996-07-20 New triazolopurines, process for their preparation and their use as medicaments
CA002242097A CA2242097C (en) 1996-07-20 1998-06-26 Imidazotriazolopyrimidines, process for preparing them and their use as pharmaceutical compositions

Publications (1)

Publication Number Publication Date
ZA976331B true ZA976331B (en) 1999-01-25

Family

ID=32963000

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA976331A ZA976331B (en) 1996-07-20 1997-07-17 New imidazotriazolopyrimidines processes for their preparation and their use as pharmaceutical compositions

Country Status (25)

Country Link
EP (2) EP0978517A3 (en)
JP (1) JP3020281B2 (en)
CN (1) CN1219936A (en)
AT (1) ATE191913T1 (en)
AU (1) AU3695597A (en)
BG (1) BG102707A (en)
BR (1) BR9710747A (en)
CA (1) CA2256736A1 (en)
CZ (1) CZ265498A3 (en)
DE (2) DE19629378A1 (en)
DK (1) DK0880524T3 (en)
EE (1) EE9800451A (en)
ES (1) ES2147453T3 (en)
GR (1) GR3033842T3 (en)
HR (1) HRP970395A2 (en)
HU (1) HUP9902311A3 (en)
ID (1) ID19106A (en)
IL (1) IL126453A0 (en)
NO (1) NO983860L (en)
PL (1) PL328824A1 (en)
PT (1) PT880524E (en)
SK (1) SK114498A3 (en)
TR (1) TR199801659T2 (en)
WO (1) WO1998003511A1 (en)
ZA (1) ZA976331B (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19826843A1 (en) * 1998-06-16 1999-12-23 Boehringer Ingelheim Pharma Novel imidazotriazolopyrimidines, process for their preparation and their use as medicaments
US6492377B1 (en) 1998-06-25 2002-12-10 Boehringer Ingelheim Pharma Kg Imidazotriazolopyrimidines with adenosine-antagonistic activity
AU9347498A (en) * 1998-08-27 2000-03-21 Boehringer Ingelheim Pharma Kg Imidazotriazolopyrimidines
US7329668B2 (en) 2003-02-25 2008-02-12 Bristol-Myers Squibb Company Pyrazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same
US7071333B2 (en) 2003-07-30 2006-07-04 Bristol-Myers Squibb Company Triazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same
US7511050B2 (en) * 2006-06-23 2009-03-31 Incyte Corporation Purinone derivatives as HM74A agonists
AU2019227607C1 (en) 2018-02-27 2023-07-20 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors
EP3810610A1 (en) 2018-05-18 2021-04-28 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
CN117304191A (en) 2018-07-05 2023-12-29 因赛特公司 Fused pyrazine derivatives as A2A/A2B inhibitors
AR117164A1 (en) 2018-11-30 2021-07-14 Merck Sharp & Dohme DERIVATIVES OF AMINO-TRIAZOLOQUINAZOLINE 9-SUBSTITUTED AS ANTAGONISTS OF THE ADENOSINE RECEPTOR, PHARMACEUTICAL COMPOSITIONS AND THEIR USE FOR THE TREATMENT OF VARIOUS TYPES OF CANCER
TWI829857B (en) 2019-01-29 2024-01-21 美商英塞特公司 Pyrazolopyridines and triazolopyridines as a2a / a2b inhibitors
CN112778311B (en) * 2019-11-01 2024-06-04 上海翰森生物医药科技有限公司 Nitrogen-containing fused ring derivative inhibitor, preparation method and application thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU623755B2 (en) * 1989-03-29 1992-05-21 Merrell Pharmaceuticals Inc. Selective adenosine receptor compounds
IT1264901B1 (en) * 1993-06-29 1996-10-17 Schering Plough S P A HETEROCYCLIC ANALOGUES OF 1,2,4-TRIAZOLE(15-C)PYRIMIDINES WITH ANTAGONIST ACTIVITY FOR THE ADENOSINE A2 RECEPTOR
JPH083169A (en) * 1994-06-15 1996-01-09 Yamasa Shoyu Co Ltd 4-Methyl-1H- [1,2,4] triazolo [1,5-a] purin-9 (4H) -ones

Also Published As

Publication number Publication date
PT880524E (en) 2000-07-31
WO1998003511A1 (en) 1998-01-29
ID19106A (en) 1998-06-18
DE59701467D1 (en) 2000-05-25
CA2256736A1 (en) 1998-01-29
GR3033842T3 (en) 2000-10-31
IL126453A0 (en) 1999-08-17
ATE191913T1 (en) 2000-05-15
EP0978517A2 (en) 2000-02-09
DK0880524T3 (en) 2000-07-17
DE19629378A1 (en) 1998-01-29
ES2147453T3 (en) 2000-09-01
NO983860L (en) 1998-10-21
BR9710747A (en) 1999-08-17
EP0978517A3 (en) 2003-11-12
CZ265498A3 (en) 1998-12-16
CN1219936A (en) 1999-06-16
EP0880524B1 (en) 2000-04-19
PL328824A1 (en) 1999-02-15
JP3020281B2 (en) 2000-03-15
HUP9902311A2 (en) 1999-10-28
HUP9902311A3 (en) 2000-06-28
AU3695597A (en) 1998-02-10
SK114498A3 (en) 1999-02-11
BG102707A (en) 1999-09-30
EE9800451A (en) 1999-06-15
HRP970395A2 (en) 1998-08-31
EP0880524A1 (en) 1998-12-02
JP2000501420A (en) 2000-02-08
TR199801659T2 (en) 1998-12-21
NO983860D0 (en) 1998-08-21

Similar Documents

Publication Publication Date Title
IL126453A0 (en) New triazolopurines method of preparing them and their use as drugs
AU686365B2 (en) New peptide compounds derived from boronic acid, process for preparing them and pharmaceutical compositions containing them
FI941987A0 (en) New amino acid derivatives, processes for their preparation and compositions containing these compounds
IL115493A (en) Derivatives of esters and amides of carbolinyl- carbazolyl- cycloalkano-indolyl-and azaindolymethyl-benzeneacetic acid their preparation and pharmaceutical compositions containing them
HUT74093A (en) Oxazolidinone derivatives as adhesion-receptor antagonists, pharmaceutical compositions containing them and process for their preparation
AU9079198A (en) Indolecarboxylic compounds and their use as pharmaceutical compounds
TR199801644T2 (en) Oxave tiya-diazole iéeren muscarinic receptor antagonist
PL335954A1 (en) Novel cyclic compounds compounds comprising a cycloalkylene chain, method of obtaining them and pharmaceutic compositions containing such compounds
HU9800964D0 (en) New heterocyclic compounds, a process for their preparation and pharmaceutical compositions containing them
AU4538397A (en) New benzopyran compounds, process for preparing them and pharmaceutical compositions containing them
ZA200006730B (en) Camptothecin analogue compounds, a process for their preparation and pharmaceutical compositions containing them.
HUT76480A (en) Alkyl-5-methyl-sulphonyl-benzoyl-guanidine derivatives, process for the preparation thereof and pharmaceutical compositions containing them
ATE242201T1 (en) SUBSTITUTED DIMERIC COMPOUNDS, METHOD FOR THE PRODUCTION THEREOF AND THEIR PHARMACEUTICAL COMPOSITIONS
FI950681A0 (en) New acronysin analogs, process for their preparation, and pharmaceutical compositions containing these compounds
HUT50785A (en) Method for producing intermediate products of anellated azepinone and azocynone derivatives
HUP9903452A2 (en) Pyrrolidinyl and pyrrolinyl ethylamine compounds as kappa agonists, process for producing them and pharmaceutical compositions containing them
IL59803A0 (en) Oxazoline and thiazoline derivatives,their preparation and pharmaceutical compositions containing them